The Milly Apthorp Charitable Trust awards £300,000 to Myeloma UK for two key projects
Myeloma UK has been awarded its largest grant to date from a charitable trust.
The Milly Apthorp Charitable Trust has awarded Myeloma UK a total of £300,000 to be spent over the next two-three years, including £190,000 for the Myeloma UK Early Phase Clinical Trial Network and £110,000 for a project called “Pass Mark”.
The Myeloma UK Early Phase Clinical Trial Network is an innovative collaboration funded by Myeloma UK which brings together for the first time clinical specialists and researchers, the pharmaceutical industry, the NHS and government to conceive, design and manage a prioritised portfolio of early phase trials of novel myeloma drugs in the UK. The Clinical Trial Network was launched in November 2009 and the grant will help fund the first three trials to take place within the network.
The “Pass Mark” project is a myeloma-specific standards framework that will ensure the delivery of excellence in clinical care and good practice underpinned by patient needs. It will draw down on existing cancer initiatives and make them specific and customised to myeloma in order to reflect its multi-faceted, complex and heterogenic nature. Myeloma UK will use “Pass Mark” to recognise hospitals that demonstrate excellence and encouraging improvements where necessary.
Established in 1982 by Milly Apthorp, her son, philanthropist John Apthorp OBE and Lawrence Fenton FCA, the Trust has awarded the grant to Myeloma UK through its general grants programme.
Speaking about the award, Myeloma UK Chief Executive, Eric Low said:
“I am thrilled that The Milly Apthorp Charitable Trust has chosen to support these two vital projects and we are extremely grateful to the Trustees for selecting us for this award. Without doubt these projects have the ability to transform the landscape for myeloma. We look forward to making significant progress with these projects over the next few years.”
|